Patrice Cacoub, Arielle Elmaleh-Sachs, Isabelle Poizot-Martin, Cecile Goujard, Patrick Miailhes, Philippe Morlat, Julie Chas, Isabelle Goderel, Philippe Halfon, Francois Caron, David Rey, Francois Boue, Anne Simon, Stanislas Pol, Eric Rosenthal and The GERMIVIC Study Group
Aim: To analyze HCV care and treatment in HIV-HCV coinfected patients and their evolution between 2006 and2013, in France.Patients and
methods: HIV-HCV consecutive seropositive patients were prospectively included in two crosssectional
studies from April 3 to 10, 2006 (n=416) and from April 8 to 15, 2013 (n=342). A standard data collection
form was used.
Results: Patients in 2013 compared to those in 2006 had undetectable HIV viral load and negative HCV viremia more often (82% vs. 69%, and 48% vs. 27%, respectively), with more frequent co-infection by HCV genotype 1 and 4. Liver biopsy was done less frequently (5% vs. 35%). Non-invasive liver damage assessment was done more frequently (42% vs. 22%), using serum biomarkers (37% vs. 67%) or liver-stiffness methods (69% vs. 11%). A sustained virological response to HCV treatment was more frequent (50% vs. 30%). In both surveys, patients who had received HCV treatment compared to those who had never been treated were more often of European origin, had better control of their HIV infection, had more frequent liver damage assessments and were less frequently infected by a genotype 4.
Conclusion: In comparison to 2006, more co-infected patients in 2013 had better control of their HIV infection, had liver damage assessment, received HCV treatment and more frequently had a sustained virological response. New anti-HCV combinations with greater efficacy and less toxicity should soon modify the present picture.
Share this article
Journal of AIDS & Clinical Research received 5061 citations as per Google Scholar report
